HB 892 was heard by the Public Health Committee on Tuesday, April 28, 2015. Thank you to C.A.F.E. Texas families and epilepsy experts testified before the committee on behalf of HB 892 this morning.
SB 339 will be heard by the Senate Health and Human Services Committee at 8:00am Wednesday, April 29, 2015.
C.A.F.E. Texas would like to extend a sincere thank you to Rep Myra Crownover, Chair of the Public Health Committee and Sen. Charles Schwertner, Chair of the Senate Health & Human Services Committee for scheduling the hearings. Please join us in thanking the members of the committees and co-authors of HB 892 and SB 339 listed below:
Another important development is that HB 892 and SB 339 have undergone a thorough review. Below is a recap of some of the language revisions:
1. Definition of “Intractable Epilepsy” (as in HB 892 / SB 339)
"Intractable epilepsy" means a seizure disorder in which the patient’s seizures have been treated by two or more (1) appropriately chosen and (2) maximally titrated antiepileptic drugs that have failed to control the seizures.
2. Utilization of CBD Oil must meet following requirements:
(1) the patient is a permanent resident of Texas;
(2) the physician complies with the DPS registration requirements; and
(3) the physician certifies to DPS that:
(A) the patient is diagnosed with "intractable epilepsy";
(B) the physician determines the risk of the medical use of low-THC cannabis
by the patient is reasonable in light of the potential benefit for the patient; and
(C) a second physician qualified to prescribe low-THC cannabis under DPS
rules has concurred with the determination first treating physician.
Thank you for your continued support of C.A.F.E. Texas. Stay tuned for developments!